机构：[1]Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China[2]Beijing Key Laboratory of Drug Target Identification and Drug Screening Beijing 100050, China[3]Xuanwu Hospital, Capital Medical University, Beijing 100053, China首都医科大学宣武医院
Type 2 diabetes patients have an increased risk of developing hepatic fibrosis. Salvianolic acid A (SalA) has been reported to be a strong polyphenolic anti-oxidant and free radical scavenger. The aim of the present study was to evaluate the effect of SalA on the pathological progression of hepatic fibrosis in high-fat diet (HFD)-fed and streptozotocin (STZ)-induced diabetic rats and to clarify the underlying mechanisms. Type 2 diabetic animal model with hepatic fibrosis was developed by a high-sucrose, HFD and low-dose STZ injection (i: p:). Diabetic rats were randomly divided into SalA group (0.3 mg/kg/day) and diabetic control groups fed with a HFD. After administration for four months, SalA reversed the hyperlipidemia and reduced hepatic triglyceride (TG). Hematoxylin-Eosin (HE) and Picro acid-Sirius red staining results indicated that SalA significantly alleviated the lesions of hepatic steatosis and fibrosis, with the reduction of type I and III collagens. The expression of alpha-smooth-muscle-actin (alpha-SMA) and transforming growth factor beta 1 (TGF-beta 1) in the liver were markedly down-regulated by SalA treatment. TUNEL staining showed that SalA reduced apoptosis in hepatocytes. In addition, SalA improved hepatic mitochondrial respiratory function in diabetic rats. Taken together, these findings demonstrated that SalA could prevent the pathological progression of hepatic fibrosis in HFD-fed and STZ-induced diabetic rats. The underlying mechanisms may be involved in reducing oxidative stress, suppressing alpha-SMA and TGF-beta 1 expression, as well as exerting anti-apoptotic and mitochondria-protective effects.
基金：
the Key Project for Drug Innovation (2009ZX09102-123,
2009ZX09302-003) and the International Project (2008DFA31710) from the Ministry of Science and Technology of China,
National Natural Science Foundation of China (81102492).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2013]版：
大类|4 区医学
小类|3 区全科医学与补充医学3 区医学：内科
最新[2025]版：
大类|2 区医学
小类|2 区全科医学与补充医学2 区医学：内科
JCR分区：
出版当年[2012]版：
Q1INTEGRATIVE & COMPLEMENTARY MEDICINEQ1MEDICINE, GENERAL & INTERNAL
最新[2023]版：
Q1INTEGRATIVE & COMPLEMENTARY MEDICINEQ1MEDICINE, GENERAL & INTERNAL
第一作者机构：[1]Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
共同第一作者：
通讯作者：
通讯机构：[*1]National Center for Pharmaceutical Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences, 1 Xian Nong Tan Street, Xi Cheng District, Beijing 100050, P. R. China.
推荐引用方式(GB/T 7714)：
Guifen Qiang ,Xiuying Yang ,Qi Xuan ,et al.Salvianolic Acid A Prevents the Pathological Progression of Hepatic Fibrosis in High-Fat Diet-Fed and Streptozotocin-Induced Diabetic Rats[J].AMERICAN JOURNAL OF CHINESE MEDICINE.2014,42(5):1183-1198.doi:10.1142/S0192415X14500748.
APA：
Guifen Qiang,,Xiuying Yang,,Qi Xuan,,Lili Shi,,Hengai Zhang,...&Guanhua Du.(2014).Salvianolic Acid A Prevents the Pathological Progression of Hepatic Fibrosis in High-Fat Diet-Fed and Streptozotocin-Induced Diabetic Rats.AMERICAN JOURNAL OF CHINESE MEDICINE,42,(5)
MLA：
Guifen Qiang,,et al."Salvianolic Acid A Prevents the Pathological Progression of Hepatic Fibrosis in High-Fat Diet-Fed and Streptozotocin-Induced Diabetic Rats".AMERICAN JOURNAL OF CHINESE MEDICINE 42..5(2014):1183-1198
